RxDoctor Payments Data

Margaret Zachewicz, PA

Medical · New Wilmington, PANPI 1407961998

Payments from drug & device makers

$10,348in general payments, 2019–2025

Across 626 payments — averaging $16.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • AstraZeneca$595
  • Pfizer$385
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$10,18798%
  • Education$1612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$10,348 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$12,110
Medicare patients
64
Services billed
167

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide50$50,511
JardianceEmpagliflozin41$37,596
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$27,168
FarxigaDapagliflozin Propanediol23$23,087
RexultiBrexpiprazole15$20,337
MounjaroTirzepatide13$17,011
GlyxambiEmpagliflozin/Linagliptin22$13,023
Synjardy XrEmpagliflozin/Metformin Hcl12$12,055
XareltoRivaroxaban18$10,230
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$10,055
Breztri AerosphereBudesonide/Glycopyr/Formoterol14$9,035
TradjentaLinagliptin12$6,197
Levothyroxine Sodium250$2,160
Atorvastatin Calcium204$1,822
Lantus SolostarInsulin Glargine,hum.Rec.Anlog16$1,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Synjardy Xr, Tradjenta$375$68,87187 claims
Novo NordiskOzempic$1,045$50,51150 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,515$37,22441 claims
AstraZenecaFarxiga, Breztri Aerosphere$595$32,12237 claims
Otsuka America Pharmaceutical, Inc.Rexulti$227$20,33715 claims
Lilly USA, LLCMounjaro$1,106$17,01113 claims
Johnson & JohnsonXarelto$331$10,23018 claims
AbbVieSynthroid$1,133$1,05319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.

Other medical in New Wilmington

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →